211 related articles for article (PubMed ID: 33254439)
1. Development of small molecule inhibitors/agonists targeting STING for disease.
Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
[TBL] [Abstract][Full Text] [Related]
2. Delivery of STING agonists for cancer immunotherapy.
Wang J; Meng F; Yeo Y
Curr Opin Biotechnol; 2024 Jun; 87():103105. PubMed ID: 38461748
[TBL] [Abstract][Full Text] [Related]
3. cGAS-STING, an important signaling pathway in diseases and their therapy.
Li Q; Wu P; Du Q; Hanif U; Hu H; Li K
MedComm (2020); 2024 Apr; 5(4):e511. PubMed ID: 38525112
[TBL] [Abstract][Full Text] [Related]
4. An updated patent review of stimulator of interferon genes agonists (2021 - present).
Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
6. Unlocking the promise of systemic STING agonist for cancer immunotherapy.
Sun X; Zhou X; Lei YL; Moon JJ
J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564
[TBL] [Abstract][Full Text] [Related]
7. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
8. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
9. A next-generation STING agonist MSA-2: From mechanism to application.
Yang J; Luo Z; Ma J; Wang Y; Cheng N
J Control Release; 2024 Jul; 371():273-287. PubMed ID: 38789087
[TBL] [Abstract][Full Text] [Related]
10. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
11. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
[TBL] [Abstract][Full Text] [Related]
12. Nanoformulations of chemotherapeutic activators of the cGAS-STING pathway in tumor chemoimmunotherapy.
Wang L; Yu Z; Zhang J; Guo J
Drug Discov Today; 2024 Mar; 29(3):103892. PubMed ID: 38272174
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitor Palbociclib targets STING to alleviate autoinflammation.
Gao J; Zheng M; Wu X; Zhang H; Su H; Dang Y; Ma M; Wang F; Xu J; Chen L; Liu T; Chen J; Zhang F; Yang L; Xu Q; Hu X; Wang H; Fei Y; Chen C; Liu H
EMBO Rep; 2022 Jun; 23(6):e53932. PubMed ID: 35403787
[TBL] [Abstract][Full Text] [Related]
14. piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization.
Zhuo SH; Wang TY; Zhao L; Su JY; Hu JJ; Zhao YF; Li YM
Angew Chem Int Ed Engl; 2024 May; ():e202407037. PubMed ID: 38767062
[TBL] [Abstract][Full Text] [Related]
15. The discovery of potent small molecule cyclic urea activators of STING.
Basu S; Middya S; Banerjee M; Ghosh R; Pryde DC; Yadav DB; Shrivastava R; Surya A
Eur J Med Chem; 2022 Feb; 229():114087. PubMed ID: 34998056
[TBL] [Abstract][Full Text] [Related]
16. Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer.
Alnukhali M; Altabbakh O; Farooqi AA; Pollack A; Daunert S; Deo S; Tao W
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38347787
[TBL] [Abstract][Full Text] [Related]
17. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents.
Feng X; Pan L; Qian Z; Liu D; Guan X; Feng L; Song B; Xu X; Tan N; Ma Y; Li Z; Wang Z; Bian J
J Med Chem; 2022 Nov; 65(22):15048-15065. PubMed ID: 36069713
[TBL] [Abstract][Full Text] [Related]
19. M335, a novel small-molecule STING agonist activates the immune response and exerts antitumor effects.
Zhao M; Fan W; Wang Y; Qiang P; Zheng Z; Shan H; Zhang M; Liu P; Wang Y; Li G; Li M; Hong L
Eur J Med Chem; 2024 Jan; 264():116018. PubMed ID: 38091891
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel amidobenzimidazole derivatives as orally available small molecule modulators of stimulator of interferon genes for cancer immunotherapy.
Jeon MJ; Lee H; Jo S; Kang M; Jeong JH; Jeong SH; Lee JY; Song GY; Choo H; Lee S; Kim H
Eur J Med Chem; 2023 Dec; 261():115834. PubMed ID: 37862818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
